EBS LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Emergent Biosolutions Inc. Shareholders

New York, New York--(Newsfile Corp. - May 25, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Emergent Biosolutions Inc. (NYSE: EBS).

CLICK HERE FOR MORE DETAILS:

https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=16172&from=5

Affected shareholders purchased shares of EBS between July 6, 2020 and March 31, 2021

Shareholders interested in representing the class of wronged shareholders have until June 18, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Emergent Biosolutions Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85209